The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization to Abbott for its BinaxNow COVID-19 Ag Card test, a virtually guided at-home rapid COVID-19 test. The test delivers results within 15 minutes.
The test uses the digital health platform from eMed, with Abbott's complementary Navica app to guide consumers through the testing process. The app displays authenticated BinaxNow test results that are verified by a trained guide; it costs about $25 for the test.
Abbott and eMed are expected to deliver and administer 30 million tests in the first quarter of 2021. An additional 90 million are expected in the second quarter, according to the company.